Context Therapeutics Inc. (CNTX) Earnings History
Annual and quarterly earnings data from 2019 to 2025
Loading earnings history...
CNTX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CNTX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export CNTX earnings history in CSV or JSON format
Free sign-in required to download data
Context Therapeutics Inc. (CNTX) Earnings Overview
As of May 8, 2026, Context Therapeutics Inc. (CNTX) reported trailing twelve-month net income of -$40M, reflecting +17.4% year-over-year growth. The company earned $-0.42 per diluted share over the past four quarters.
Looking at the long-term picture, CNTX's historical earnings data spans multiple years. The company achieved its highest annual net income of $7M in fiscal 2020.
Context Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including AGEN ($115,000 net income, 0.1% margin), IMVT (-$464M net income), ONCO (-$14M net income, -1721.0% margin), CNTX has comparable earnings metrics. Compare CNTX vs AGEN →
CNTX Earnings vs Peers
Earnings metrics vs comparable public companies
CNTX Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$36M | -35.2% | -$40M | $-0.38 | - | - |
| 2024 | -$27M | -11.5% | -$30M | $-0.46 | - | - |
| 2023 | -$24M | -61.5% | -$25M | $-1.50 | - | - |
| 2022 | -$15M | -41.9% | -$15M | $-0.93 | - | - |
| 2021 | -$10M | -257.4% | -$11M | $-3.69 | - | - |
| 2020 | $7M | +204.1% | -$3M | $-0.80 | - | - |
| 2019 | -$6M | - | -$5M | $-0.68 | - | - |
See CNTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CNTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CNTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCNTX — Frequently Asked Questions
Quick answers to the most common questions about buying CNTX stock.
Is CNTX growing earnings?
CNTX EPS is $-0.42, with earnings growth accelerating to +17.4%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-40M.
What are CNTX's profit margins?
Context Therapeutics Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are CNTX's earnings?
CNTX earnings data spans 2019-2025. The accelerating earnings trend is +17.4% YoY. Historical data enables comparison across business cycles.